Thursday, October 8, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleUk· February 27, 2026

Stocks to watch next week: Broadcom, Costco, Adidas, Aviva and Greggs

View original at uk.finance.yahoo.com
Stocks to watch next week: Broadcom, Costco, Adidas, Aviva and Greggs The latest earnings season is winding down but there are still a number of major companies due to report in the week ahead…
Opening lines of the source · Uk · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Greggs expects to open around 120 net new shops in 2026

    80% confidence
  • Aviva is on track to achieve 2026 group targets one year early, expecting to deliver operating profit above £2bn in 2025 at around £2.2bn

    80% confidence
  • Aviva's share price performance follows a series of disposals to slim down the business, strong earnings, consistent dividend growth and the well-received acquisition of Direct Line

    80% confidence
  • Some analysts are suggesting that Aviva may resume share buybacks in 2026 at a rate of around £350m a year, after a gap in 2025 following the Direct Line deal

    80% confidence
  • Nervous retailers in the US were ordering less product upfront as they waited to understand the full impact of president Donald Trump's tariffs

    80% confidence
  • Profitability is anticipated to come under pressure as the growing contribution of lower-margin, full rack-scale AI solutions weighs on overall margins as FY2026 progresses

    80% confidence
  • Unhelpful changes to tax rules and minimum wages, slowing UK economic growth, and cost-conscious consumers are all weighing on the outlook

    80% confidence
  • Broadcom expects adjusted EBITDA to come at 67% of projected revenue

    80% confidence
  • The improved profitability outlook reflects continued brand momentum, the better-than-expected business performance, as well as the company's successful efforts to partly mitigate the additional costs resulting from increased US tariffs

    80% confidence
  • Analyst consensus reflects expectations for sustained revenue momentum, primarily driven by continued expansion in the AI semiconductor segment

    80% confidence
  • Aviva aims to deliver operating EPS growth at an annual compound rate of 11%, take return on equity above 20% and return £7bn in cash to shareholders over three years

    80% confidence
  • Full-year pre-tax profit guidance remains intact, expected to land at around £173m, down 9% on the prior year

    80% confidence
  • The group's expected to say that underlying profits will flatline in 2026

    80% confidence
  • Broadcom expects first quarter revenue of approximately $19.1bn, up 28% year-over-year

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com